Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

28.38 +0.57 (+2.03%)
Streaming Delayed Price Updated: 10:03 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More ↗
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
News headline image
Best Stocks To Buy Now: June 02, 2022
The stock market continues to be one of the best ways for regular investors to build wealth over time. The 
Via Best Stocks
Topics Artificial Intelligence Cannabis
News headline image
Sarissa Condemns Poor Corporate Governance at Alkermes
From Sarissa Capital Management LP
Via Business Wire
News headline image
Recap: Alkermes Q1 Earnings ↗
Alkermes (NASDAQ:ALKS) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Expert Ratings for Alkermes ↗
Alkermes (NASDAQ:ALKS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
New Findings About Life With Bipolar 1 Disorder
SOURCE: Alkermes 
Via 3BL Media
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
Via FinancialNewsMedia
News headline image
Treating Bipolar 1 Disorder
SOURCE: Alkermes 
Via 3BL Media
News headline image
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22 ↗
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing... 
Via Talk Markets
News headline image
Alkermes Awarded 2022 Platinum Bell Seal for Workplace Mental Health
SOURCE: Alkermes 
Via 3BL Media
News headline image
Tips to Improve Mental Well-Being
SOURCE: Alkermes 
Via 3BL Media
News headline image
Alkermes Celebrates National Women's Health Week by Reminding You Why Regular Cancer Screenings Are Vital
SOURCE: Alkermes 
Via 3BL Media
News headline image
Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month
SOURCE: Alkermes 
Via 3BL Media
News headline image
Looking Into Alkermes's Return On Capital Employed ↗
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter. 
Via Benzinga
News headline image
61 Biggest Movers From Yesterday ↗
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with... 
Via Benzinga
News headline image
38 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Vivakor, Inc. (NASDAQ: VIVK) gained 154% to $4.3550 after the company announced it has signed a 10-year contract with Hot Oil Transport with a potential value of... 
Via Benzinga
News headline image
LGBTQ+ People Are More Likely to Experience a Mental Health Condition
SOURCE: Alkermes 
Via 3BL Media
Topics LGBTQ
News headline image
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Alkermes's Earnings Outlook ↗
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
News headline image
Alkermes Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗
Alkermes (NASDAQ:ALKS) will host a conference call at 08:00 AM ET on April 27, 2022, to discuss Q1 2022 earnings results. How to Attend Alkermes (ALKS) Conference Call Follow this link to access the... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen ↗
 
Via Benzinga
News headline image
This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As it pushes ahead with expansion into the United States,... 
Via Benzinga
News headline image
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction ↗
Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops ↗
Sentiment was low heading into the study and analysts aren't hopeful for other tests. 
Via Investor's Business Daily
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric... 
Via FinancialNewsMedia
Topics Economy
News headline image
The Ruble Is Rubble ↗
MSCI says Russian companies are 
Via Talk Markets
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.